These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22884551)

  • 1. Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn?
    Koné-Paut I; Piram M
    Autoimmun Rev; 2012 Nov; 12(1):77-80. PubMed ID: 22884551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
    Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
    Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
    Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
    Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
    Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
    Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
    Feist E; Burmester GR
    Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
    Church LD; McDermott MF
    Curr Opin Mol Ther; 2009 Feb; 11(1):81-9. PubMed ID: 19169963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
    Curran MP
    BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
    Arnold DD; Yalamanoglu A; Boyman O
    Front Immunol; 2022; 13():888392. PubMed ID: 35874710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilonacept--CAPS and beyond.
    Stahl N; Radin A; Mellis S
    Ann N Y Acad Sci; 2009 Dec; 1182():124-34. PubMed ID: 20074281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.
    Kullenberg T; Löfqvist M; Leinonen M; Goldbach-Mansky R; Olivecrona H
    Rheumatology (Oxford); 2016 Aug; 55(8):1499-506. PubMed ID: 27143789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
    Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
    Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
    Savic S; McDermott MF
    Nat Rev Rheumatol; 2009 Oct; 5(10):529-30. PubMed ID: 19798026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.